IR News
-
Consolidated Financial Report for the 3rd Quarter of the Fiscal Year 2021
-
Supplemental Documents for 3rd Quarter of Fiscal Year 2021
-
Notice concerning revision (upward revision) of full-year earnings forecast
-
Notice concerning recording of extraordinary loss (impairment loss)
-
Notice concerning selection of "Prime Market" under new market segments
-
Financial Result for 2nd Quarter of Fiscal Year 2021
-
Consolidated Financial Report for 2nd Quarter of Fiscal Year 2021(April 1, 2021 through September 30, 2021)
-
Supplemental Documents for 2nd Quarter of Fiscal Year 2021
-
Notice concerning revision of full-year earnings forecast
-
Notice concerning increase in dividend of surplus (interim dividend)
-
Notice of passing eligibility examination as active pharmaceutical ingredient (API) producing facility by US Food and Drug Administration (FDA)
-
Consolidated Financial Report for 1st Quarter of Fiscal Year 2021(April 1, 2021 through June 30, 2021)
-
Supplemental Documents for 1st Quarter of Fiscal Year 2021
-
Partial amendment of "NOTICE OF THE 106th ORDINARY GENERAL SHAREHOLDERS' MEETING"
-
(Updated) Partial revisions of "Consolidated Financial Results for the Year ended March 31, 2021" and "Supplemental Documents for FY2020"
-
Notice of the 106th Ordinary General Shareholders' Meeting
-
Financial Result for Fiscal Year 2020
-
Supplemental Documents for Fiscal Year 2020
-
Consolidated Financial Results for Fiscal Year 2020 (April 1, 2020 through March 31, 2021)